CorRen Medical Secures $2.4M Grant to Revolutionize PAD Diagnosis with UltraSense ABI Technology

CorRen Medical Inc. is thrilled to announce a successful funding round that raised $2,400,000, marking a significant milestone in the company’s mission to transform the diagnosis and treatment of Peripheral Artery Disease (PAD). At the forefront of medical innovation, CorRen is dedicated to developing an autonomous, hands-free Ankle Brachial Index (ABI) test that addresses the long-standing challenges of current ABI testing methods, such as complexity and time constraints. Their flagship product, UltraSense, is engineered to simplify and streamline PAD diagnosis by offering a highly accurate, user-friendly, and reimbursable solution that has the promise to revolutionize how PAD is detected and managed globally. With the worldwide market potential for ABI testing equipment estimated at $1.6 billion, this new capital infusion will empower CorRen to accelerate research and development, refine its technology, and advance regulatory approvals to ensure rapid and widespread adoption. The funding will also support strategic partnerships and expand clinical trials, aligning with the company’s vision to make PAD testing accessible and efficient for both patients and healthcare providers. By targeting a critical gap in the market, CorRen is setting the stage to not only improve patient outcomes but also reduce the burden on healthcare systems worldwide. This investment underscores the confidence of the investor community in CorRen’s innovative approach and the transformative impact of UltraSense, paving the way for a new era in PAD diagnosis and treatment. With this fresh capital, CorRen Medical Inc. is poised to lead the next wave of innovation, bringing cutting-edge technology closer to clinicians and patients who need it the most.